CorMedix Inc

CorMedix reported second quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, and reaffirmed full-year revenue guidance of $325 million to $345 million while raising adjusted EBITDA guidance to $125 million to $140 million. The company also announced a multi-year commercial supply agreement for DefenCath with an additional large dialysis organization, bringing commercial supply agreements to all five top U.S. dialysis providers. CorMedix anticipates submission of the sNDA for REZZAYO in prophylaxis in the third quarter, with potential FDA action in the first half of 2027. Second quarter DefenCath sales were $66.1 million, and revenue from the acquired Melinta portfolio was $35.8 million. Net income was $26.0 million, or $0.33 per basic share, and cash and cash equivalents ended the quarter at $256.7 million.

The iShares US Pharmaceuticals ETF has an implied analyst target price of $109.89 per unit based on its underlying holdings, representing a 9.68% upside from its recent trading price near $100.19. Three holdings with notable upside potential are Crinetics Pharmaceuticals, CorMedix, and Zoetis, which together account for 5.04% of the ETF. Crinetics Pharmaceuticals has an average analyst target of $83.14 per share, 97.82% above its recent price of $42.03. CorMedix has a target of $14.00, implying 59.27% upside from $8.79, while Zoetis is expected to reach $114.12, a 51.32% increase from $75.42.

CorMedix is transitioning from a launch-driven story centered on its catheter lock solution DefenCath into a broader test of commercial durability, portfolio integration, and reimbursement execution. DefenCath, the first and only FDA-approved antimicrobial catheter lock solution in the U.S., generated first-quarter 2026 net revenues of $97.5 million and has multi-year agreements covering roughly 60% of the U.S. outpatient dialysis market. The August 2025 acquisition of Melinta Therapeutics added six marketed infectious disease products and Toprol-XL, contributing $45.5 million in revenues in 2025 after the deal closed and $29.9 million in the first quarter of 2026, with expected annual cost synergies of $35 million to $45 million. Within the Melinta portfolio, Rezzayo is seen as the most important growth option, with a current treatment market estimated at $250 million to $350 million and a potential prophylaxis indication targeting a U.S. market of more than $2 billion following positive phase III ReSPECT study results. However, DefenCath faces a significant reimbursement decline starting July 1, 2026, as it moves to the post-adjustment add-on phase, which is expected to reduce net pricing in the second half of the year and create uneven quarterly revenues. The stock carries a Zacks Rank #3 (Hold) with Value, Growth, Momentum, and VGM Scores all of A, indicating strong characteristics across valuation, growth, and momentum but suggesting the earnings revision picture is not yet strong enough for a more aggressive call.

CorMedix delivered a dramatic 2025 reset with total revenues rising to $311.7 million from $43.5 million in 2024, led by DefenCath generating $258.8 million. Momentum continued into the first quarter of 2026 with net revenues of $127.4 million, though a non-recurring $9 million favorable change in estimate tied to sales allowances boosted results. The company holds $178.1 million in cash and investments against $145 million in long-term debt, funding operations through at least mid-2027. However, DefenCath is transitioning from Transitional Drug Add-on Payment Adjustment support to a post-payment add-on phase, expected to pressure net pricing in the second half of 2026. CorMedix also faces competition from Pfizer and Amphastar Pharmaceuticals, while preparing for a potential Rezzayo launch in a new prophylaxis indication with a regulatory filing targeted for the second half of 2026.

Within3, the leading Launch Intelligence platform for life sciences, has appointed Erin Mistry as Chief Executive Officer. Mistry brings more than 20 years of experience in global biopharma commercialization, having launched and priced more than 20 pharmaceutical products across eight therapeutic areas. Most recently, she served as Chief Commercial Officer at CorMedix, where she led the launch of DefenCath and drove the company to break-even within six months and profitability in under a year. As CEO, Mistry will drive the expansion of Within3's Launch Intelligence platform and services, helping pharmaceutical teams unify fragmented data, anticipate market shifts, and act with confidence at every stage of launch.